Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 151,667 |
|
|||||
| News | - | ||||||
| Day High | 1.12 | Low High |
|||||
| Day Low | 1.04 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rain Oncology Inc | RAIN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.06 | 5.71% | 1.11 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.06 | 1.04 | 1.12 | 1.11 | 1.05 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 724 | 151,667 | $ 1.08 | $ 163,268 | - | 0.82 - 14.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:58:31 | formt | 900 | $ 1.11 | USD |
Rain Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 40.74M | 36.38M | - | 0 | -75.72M | -2.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rain Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RAIN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.05 | 1.12 | 0.99 | 1.05 | 78,711 | 0.06 | 5.71% |
| 1 Month | 1.12 | 1.1444 | 0.99 | 1.08 | 106,822 | -0.01 | -0.89% |
| 3 Months | 0.96 | 1.1444 | 0.82 | 1.00 | 167,345 | 0.15 | 15.63% |
| 6 Months | 1.10 | 1.48 | 0.82 | 1.20 | 434,413 | 0.01 | 0.91% |
| 1 Year | 7.74 | 14.48 | 0.82 | 2.58 | 548,240 | -6.63 | -85.66% |
| 3 Years | 22.10 | 23.90 | 0.82 | 4.65 | 283,638 | -20.99 | -94.98% |
| 5 Years | 22.10 | 23.90 | 0.82 | 4.65 | 283,638 | -20.99 | -94.98% |
Rain Oncology Description
| Rain Therapeutics Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. |
